tbuckley/cabot-search huggingface dataset:
Theophylline and Dialysis
Authors: DAVID ZINN
Journal: Annals of Internal Medicine (1978)

Letters and Corrections1 November 1978Theophylline and DialysisDAVID ZINN, M.D., CRUZ COSME, M.D.DAVID ZINN, M.D.Search for more papers by this author, CRUZ COSME, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-5-723_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: An extensive review of drug therapy in renal failure indicated little data was available regarding the dialyzability of theophylline (1). We recently had the opportunity to study this problem in a patient who suffered an acute asthmatic episode while in acute renal failure.A 60-year-old white woman developed acute oliguric renal failure after abdominal aortic aneurysmectomy and Dacron® graft insertion. Initially, she was treated conservatively. On the 4th postoperative day, she required acute hemodialysis for treatment of uremia and severe metabolic alkalosis secondary to nasogastric suction. Shortly before dialysis was to begin, the patient became acutely short...References1. BENNETT W, SINGER I, GOLPER T, FEIG P, and COGGINS C: Guidelines for drug therapy in renal failure. Ann Intern Med 86:754-783, 1977 LinkGoogle Scholar2. MAHER J, CASSERTI M, SHEA C, and HOHNADEL D: Peritoneal dialysis in rabbits: a study of transperitoneal flux and peritoneal permeability. Nephron 20(1):18-23, 1978 CrossrefMedlineGoogle Scholar3. ANDERSON R, GAMBERTOGLIO J, and SCHRIER R: Clinical Use of Drugs in Renal Failure. Springfield, Illinois, Charles C Thomas, 1976, p. 146 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DAVID ZINN, M.D.; CRUZ COSME, M.D.Affiliations: Henry Ford Hospital Detroit, MI 48202 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug Therapy in Renal Failure: Dosing Guidelines for Adults Part II: Sedatives, Hypnotics, and Tranquilizers; Cardiovascular, Antihypertensive, and Diuretic Agents; Miscellaneous AgentsWILLIAM M. BENNETT, M.D., RICHARD S. MUTHER, M.D., RICHARD A. PARKER, M.D., PETER FEIG, M.D., GAIL MORRISON, M.D., THOMAS A. GOLPER, M.D., IRWIN SINGER, M.D. 1 November 1978Volume 89, Issue 5_Part_1Page: 723-724KeywordsAcute renal failureDrug therapyMedical dialysisRenal failure ePublished: 1 December 2008 Issue Published: 1 November 1978 PDF downloadLoading ...
Genetic variation in immune signaling genes differentially expressed in asthmatic lung tissues
Authors: Karine Tremblay, Denise Daley, Annie Chamberland, Mathieu Lemire, Alexandre Montpetit, Michel Laviolette, Arthur W. Musk, Alan L. James, Moira Chan-Yeung, Allan Becker, Anita L. Kozyrskyj, Andrew J. Sandford, Thomas J. Hudson, Peter D. Paré, Catherine Laprise
Journal: Journal of Allergy and Clinical Immunology (2008)
The Quality of Quality-of-Life Measurements-Reply
Authors: Gordon Guyatt
Journal: JAMA (1995)

<h3>In Reply.</h3> —We appreciate the interest generated by the article by Drs Gill and Feinstein and by our Commentary. In particular, we share the viewpoint expressed by Dr Hürny and colleagues and Drs Perneger and Hudelson that empirical tests of key measurement properties are required for confidence in health-related quality-of-life (HRQL) ratings. Apparently, Dr Madorsky feels that we should not describe an accident in which a previously healthy individual becomes paraplegic as a calamity or a tragedy, nor should we acknowledge that such an event entails suffering. To us, this seems denying the obvious and contradicts our experience with many individuals and families. Society continues to discriminate against disabled people. Lack of wheelchair access in many public and private institutions is the most obvious form of what is a tendency to ignore the needs of the disabled and to peripheralize and stigmatize them. We understand that Dr Madorsky believes she
Pharmaconutrition in Acute Lung Injury
Authors: Deborah J. Cook, Daren K. Heyland
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RECURRENT IMPETIGO HERPETIFORMIS.
Authors: EMILE GAUMOND
Journal: British Journal of Dermatology (1956)

Journal Article RECURRENT IMPETIGO HERPETIFORMIS. Get access EMILE GAUMOND, M.D. EMILE GAUMOND, M.D. Professor of Dermatology and Syphilology Laval University, Quebec, Canada Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 68, Issue 2, 1 February 1956, Pages 55–58, https://doi.org/10.1111/j.1365-2133.1956.tb12782.x Published: 01 February 1956
Stenting and endarterectomy for carotid artery stenosis did not differ for a composite of stroke, MI, or death
Authors: Howard S. Kirshner
Journal: Annals of Internal Medicine (2010)

ACP Journal Club16 November 2010Stenting and endarterectomy for carotid artery stenosis did not differ for a composite of stroke, MI, or deathHoward S. Kirshner, MDHoward S. Kirshner, MDVanderbilt University Medical Center, Nashville, Tennessee, USA (H.S.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-10-201011160-02012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationBrott TG, Hobson RW 2nd, Howard G, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11-23. https://pubmed.ncbi.nlm.nih.gov/20505173Clinical Impact RatingsHospitalists: Cardiology: Neurology: References1 Naylor AR, Bolia A, Abbott RJ, et al. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg. 1998;28:326-34. [PMID: 9719328] Google Scholar2 Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355:1660-71. [PMID: 17050890] Google Scholar3 SPACE Collaborative Group, Ringleb PA, Allenberg J, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomized non-inferiority trial. Lancet. 2006;368:1239-47. [PMID: 17027729] Google Scholar4 International Carotid Stenting Study Investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet. 2010;375:985-97. [PMID: 20189239] Google Scholar5 Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Eng J Med. 2004;351:1493-501. [PMID: 15470212] Google Scholar Author, Article, and Disclosure InformationAffiliations: Vanderbilt University Medical Center, Nashville, Tennessee, USA (H.S.K.)This article was published at Annals.org on 2 November 2010. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 November 2010Volume 153, Issue 10Page: JC5-12KeywordsAtrial fibrillationCarotid arteriesCarotid endarterectomyMyocardial infarctionSafetyStenosisStent implantationStrokeSurgeryUnstable angina ePublished: 16 November 2010 Issue Published: 16 November 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Interactions of Other Hemoglobin Variants with Sickle-Cell Hemoglobin
Authors: Helen M. Ranney
Journal: New England Journal of Medicine (1970)

Deoxygenation-induced sickling of erythrocytes and gelling of hemolysates containing sickle-cell hemoglobin (Hb) are manifestations of the tendency of deoxyhemoglobin S in concentrated solutions to aggregate with the formation of gels or tactoids (liquid crystals). When a deoxygenated hemoglobin mixture contains both Hb S and Hb A (or certain non-Hb S variants) the nonsickling hemoglobin participates in the formation of the long gel-forming polymers, which have been observed in erythrocytes and in concentrated hemoglobin solutions. Although the precise organization of these polymers has not been defined, it is clear from clinical and laboratory investigations of patients whose red cells contain Hb . . .
Abstract IA21: Transcriptional programs directed by the androgen receptor splice variants
Authors: Rong Hu, Changxue Lu, Elahe A. Mostaghel, Srinivasan Yegnasubramanian, Meltem Gurel, Clare Tannahill, Joanne Edwards, William Isaacs, Peter S. Nelson, Eric Bluemn, Stephen R. Plymate, Jun Luo
Journal: Cancer Research (2012)

Abstract Continued androgen receptor (AR) signaling is an established mechanism underlying castration-resistant prostate cancer (CRPC), and suppression of AR signaling remains a therapeutic goal of CRPC therapy. Constitutively active androgen receptor splice variants (AR-Vs) lack the AR ligand-binding domain (AR-LBD), the intended target of androgen deprivation therapies (ADT) including new CRPC therapies such as abiraterone and MDV3100. Transcriptional programs directed by the canonical full-length AR (AR-FL) are well characterized, but those directed the AR-Vs are not well understood. In addition, AR-FL and AR-Vs are both increased in CRPC, underscoring the critical importance of dissecting the complex interplay between AR-FL and AR-Vs. In this study, we employed a set of detection and targeting tools that differentiate the AR-FL and AR-Vs to investigate the functional distinctions between AR-FL and AR-V. We show that suppression of endogenous AR-FL signaling by targeting AR-LBD leads to increased AR-V expression in two cell line models of CRPC. Importantly, treatment-induced AR-Vs activate a distinct expression signature enriched for cell cycle genes without requiring the presence of AR-FL. Conversely, activation of AR-FL signaling suppresses the AR-V-mediated transcriptional programs but activates genes mainly associated with macromolecular synthesis, metabolism, and differentiation. In prostate cancer cells and CRPC xenografts treated with MDV3100 and abiraterone, increased expression of two constitutively active AR-Vs, AR-V7 and ARV567ES, but not AR-FL, parallels increased expression of the AR-driven cell cycle gene UBE2C. In addition, protein expression of AR-V7, but not AR-FL, is positively correlated with UBE2C in clinical CRPC specimens. The cumulative in vitro and in vivo evidence support an adaptive shift toward AR-V-mediated signaling in at least a subset of CRPC tumors as the AR-LBD is rendered inactive, suggesting a functional dichotomy between AR-FL and AR-Vs in a therapeutic setting. The dynamic interplay between AR signaling mediated by AR-FL and AR-V should be further explored in rational development of novel CRPC therapies and multipurpose biomarkers for CRPC. Citation Format: Rong Hu, Changxue Lu, Elahe A. Mostaghel, Srinivasan Yegnasubramanian, Meltem Gurel, Clare Tannahill, Joanne Edwards, William Isaacs, Peter S. Nelson, Eric Bluemn, Stephen R. Plymate, Jun Luo. Transcriptional programs directed by the androgen receptor splice variants [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr IA21.
Predicting Treatment Response to Cognitive Behavioral Therapy in Panic Disorder With Agoraphobia by Integrating Local Neural Information
Authors: Tim Hahn, Tilo Kircher, Benjamin Straube, Hans-Ulrich Wittchen, Carsten Konrad, Andreas Ströhle, André Wittmann, Bettina Pfleiderer, Andreas Reif, Volker Arolt, Ulrike Lueken
Journal: JAMA Psychiatry (2014)

Although neuroimaging research has made substantial progress in identifying the large-scale neural substrate of anxiety disorders, its value for clinical application lags behind expectations. Machine-learning approaches have predictive potential for individual-patient prognostic purposes and might thus aid translational efforts in psychiatric research.To predict treatment response to cognitive behavioral therapy (CBT) on an individual-patient level based on functional magnetic resonance imaging data in patients with panic disorder with agoraphobia (PD/AG).We included 49 patients free of medication for at least 4 weeks and with a primary diagnosis of PD/AG in a longitudinal study performed at 8 clinical research institutes and outpatient centers across Germany. The functional magnetic resonance imaging study was conducted between July 2007 and March 2010.Twelve CBT sessions conducted 2 times a week focusing on behavioral exposure.Treatment response was defined as exceeding a 50% reduction in Hamilton Anxiety Rating Scale scores. Blood oxygenation level-dependent signal was measured during a differential fear-conditioning task. Regional and whole-brain gaussian process classifiers using a nested leave-one-out cross-validation were used to predict the treatment response from data acquired before CBT.Although no single brain region was predictive of treatment response, integrating regional classifiers based on data from the acquisition and the extinction phases of the fear-conditioning task for the whole brain yielded good predictive performance (accuracy, 82%; sensitivity, 92%; specificity, 72%; P < .001). Data from the acquisition phase enabled 73% correct individual-patient classifications (sensitivity, 80%; specificity, 67%; P < .001), whereas data from the extinction phase led to an accuracy of 74% (sensitivity, 64%; specificity, 83%; P < .001). Conservative reanalyses under consideration of potential confounders yielded nominally lower but comparable accuracy rates (acquisition phase, 70%; extinction phase, 71%; combined, 79%).Predicting treatment response to CBT based on functional neuroimaging data in PD/AG is possible with high accuracy on an individual-patient level. This novel machine-learning approach brings personalized medicine within reach, directly supporting clinical decisions for the selection of treatment options, thus helping to improve response rates.
Cancer-Associated Fibroblasts Enhance the Gland-Forming Capability of Prostate Cancer Stem Cells
Authors: Chun-Peng Liao, Helty Adisetiyo, Mengmeng Liang, Pradip Roy-Burman
Journal: Cancer Research (2010)

Abstract Signals originating from cancer-associated fibroblasts (CAF) may positively regulate proliferation and tumorigenicity in prostate cancer. In this study, we investigated whether CAFs may regulate the biology of prostate cancer stem cells (CSC) by using a conditional Pten deletion mouse model of prostate adenocarcinoma to isolate both CAF cultures and CSC-enriched cell fractions from the tumors. CSCs that were isolated possessed self-renewal, spheroid-forming, and multipotential differentiation activities in tissue culture, segregating with a cell fraction exhibiting a signature expression phenotype, including SCA-1 (high), CD49f (high), CK5 (high), p63 (high), Survivin (high), RUNX2 (high), CD44 (low), CD133 (low), CK18 (low), and Androgen Receptor (low). CSC spheroid–forming efficiency was differentially influenced by the nature of fibroblasts in a coculture system: Compared with mouse urogenital sinus mesenchyme or normal prostate fibroblasts, CAFs enhanced spheroid formation, with the spheroids displaying generally larger sizes and more complex histology. Graft experiments showed that CSCs admixed with CAFs produced prostatic glandular structures with more numerous lesions, high proliferative index, and tumor-like histopathologies, compared with those formed in the presence of normal prostate fibroblasts. Together, our findings underscore a significant role of CAFs in CSC biology. Cancer Res; 70(18); 7294–303. ©2010 AACR.
PREDICTORS OF POOR OUTCOME AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE PARTNER TRIAL
Authors: Suzanne Arnold, Ajay Kirtane, Susheel Kodali, Alan Zajarias, Vinod Thourani, Philip Green, Josep Rodes–Cabau, Maria Alu, Yang Lei, Michael Mack, Martin Leon, David Cohen
Journal: Journal of the American College of Cardiology (2013)
Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients
Authors: A. Morandi, P. Pandharipande, M. Trabucchi, R. Rozzini, G. Mistraletti, A. C. Trompeo, C. Gregoretti, L. Gattinoni, M. V. Ranieri, L. Brochard, D. Annane, C. Putensen, U. Guenther, P. Fuentes, E. Tobar, A. R. Anzueto, A. Esteban, Y. Skrobik, J. I. F. Salluh, M. Soares, C. Granja, A. Stubhaug, S. E. de Rooij, E. Wesley Ely
Journal: Intensive Care Medicine (2008)
Transport of gold in the body.
Authors: E G McQueen, P W Dykes
Journal: Annals of the Rheumatic Diseases (1969)

Gold compounds continue to be used in rheuma- toid arthritis and there is good evidence to indicate that they make an effective contribution to therapy (Empire Rheumatism Council, 1960, 1961).Some data are available on the order of concentration of gold in the blood both in human subjects under treatment and in experimental animals after adminis- tration of various preparations of gold (Lawrence, 1961; Lorber, Cohen, Chang and Anderson, 1968).However, there is little information on how gold is carried by the blood.According to Simon (1954), gold in plasma after administration of colloidal Au198 is combined with , and a2 globulin fractions.Lawrence (1961) quoted Clemmeser as having found gold (material administered not specified) to be combined particularly with a, globulin, but Law- rence's own observations suggested that a substantial fraction might be bound to fibrinogen.Coke (1963) found binding to several serum protein frac- tions by aurothiomalate but particular affinity for ,-lipoprotein and 7S-y globulin.The degree of binding by plasma proteins is obviously high, and Libenson (1945) considered that there was no gold free in the plasma.Lawrence (1961) likewise found no measurable loss of gold on dialysis of serum from patients on treatment with sodium aurothiomalate.As he himself remarked, however, the enhancement of urinary excretion that follows immediately upon administration of gold salts (Freyberg, Block, and Levey 1941; Lawrence, 1961; Sliwinski, Zvaifler, and Rubin, 1966) suggests that, in the period immed- iately after injection, an appreciable fraction of the drug may be in a diffusible form.The following experiments have been performed in rabbits using Au'98-labelled sodium aurothio- malate ("Myocrisin") in an attempt to assess more accurately the carriage and distribution of this material in the body. MethodsThe animals used were sandy lop-eared rabbits aged approximately 12 months, and weighing between 3*5 and 4-0 kg.Two were pre-treated with sodium auro- thiomalate ("Myocrisin") 4 mg.(2 mg.Au)/kg.initially, then 2 mg.(1 mg.Au)/kg.weekly for 6 doses, the last one week before radioactive gold.Two rabbits received no preliminary treatment.Au'98-containing sodium aurothiomalate was obtained from the Radiochemical Centre, Amersham, having an activity of 1-95pc./ml.
Booking patients for hospital admissions: evaluation of a pilot programme for day cases
Authors: H. McLeod
Journal: BMJ (2003)

NHS patients requiring elective surgery usually have to wait before being treated and are usually told when a date becomes available.18 month pilot programme to enable day case patients to book date of hospital admission at time of decision to operate.24 pilot sites in England with relatively short waiting times and some experience of booking appointments.Proportion of patients with booked or "to come in" date during and after pilot programme, proportion not attending for admission, and proportion waiting > or = 6 months. Comparison of pilot sites with non-pilot sites.National Patients' Access Team established to help pilot sites enable patients to book admission dates. Provision of 9.9m pounds sterling to pilot sites to employ project managers, purchase equipment, buy extra time from clinical and other staff, and invest in information and communications technology.Proportion of patients with booked or "to come in" date increased from 51.1% to 72.7% between end of March 1999 and end of March 2000, and then fell to 66.2% by end of March 2001. Over the same periods, the proportion of patients waiting > or = 6 months fell from 10.9% to 10.5% and then increased to 11.9%. The proportion of patients failing to attend fell from 5.7% to 3.1% between the first quarter of 1999 and the first quarter of 2000, and then increased to 4.0% in the first quarter of 2001. Pilot sites varied widely in performance during and after the pilot phase. Pilot sites had higher proportions of patients with booked or "to come in" date than non-pilot sites at end of each period.Increasing the proportion of patients who book their date of hospital admission is possible, but there are difficulties in sustaining this. Several factors facilitated or hindered the implementation of booking, and the roll out of the programme across the NHS is seeking to incorporate these factors.
Clinical Gastroenterology: A Problem-Oriented Approach
Authors: Frank L. Iber
Journal: JAMA (1983)

Dr Cohen and 21 other physicians have produced a brief two-part book on gastroenterology. The first portion considers the clinical approach to gastrointestinal (GI) tract presentations; the second portion considers common GI tract diseases. There are 18 chapters that address the clinical management, approach, or evaluation of a stated GI tract symptom, disease, or common finding. In each, the problem is introduced and an algorithm indicating the clinical testing pattern and illustrations of the major diagnostic abnormalities are provided. The common methods of treatment, including surgery, are covered, and the expected outcomes are listed. A bibliography is present for each chapter. There are about 100 illustrations in the book printed at a size to show clearly a roentgenogram, computed tomographic scan, sonograph, or endoscopic photograph, and the majority of these clearly illustrate what is desired. The book is aimed at the medical student or the general physician who is trying
Familial Dysautonomia
Authors: Arthur I. Geltzer, Louis Gluck, Norman S. Talner, Herbert F. Polesky
Journal: New England Journal of Medicine (1964)

FAMILIAL dysautonomia has been known as a syndrome since its description by Riley et al.1 in 1949. Since their presentation the diagnosis has been made with increasing frequency in early childhood when one of the severe complications was recognized as part of the clinical picture or by a high level of suspicion after the diagnosis had been made in a sibling or close relative. The syndrome in the newborn and early infant period was examined retrospectively and only after compensatory mechanisms had been evoked and after irrevocable damage had been done to the child. This report concerns a newborn child . . .
54 ACTIVATED HEPATIC NKT CELLS RECRUIT CXCR3 EXPRESSING REGULATORY T CELLS (T REGS) INTO THE LIVER VIA A CYTOKINE-TO-CHEMOKINE CASCADE
Authors: T. Santodomingo-Garzon, J.-L. Han, T. Le, Y. Yang, M.G. Swain
Journal: Journal of Hepatology (2008)